These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 15515414)

  • 1. Trigger point injection treatment with the 5-HT3 receptor antagonist tropisetron in patients with late whiplash-associated disorder. First results of a multiple case study.
    Ettlin T
    Scand J Rheumatol Suppl; 2004; 119():49-50. PubMed ID: 15515414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-articular treatment of arthritides and activated osteoarthritis with the 5-HT3 receptor antagonist tropisetron. A double-blind study compared with methylprednisolone.
    Samborski W; Stratz T; Mackiewicz S; Müller W
    Scand J Rheumatol Suppl; 2004; 119():51-4. PubMed ID: 15515415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron.
    Müller W; Stratz T
    Scand J Rheumatol Suppl; 2004; 119():44-8. PubMed ID: 15515413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of tendopathies with tropisetron.
    Stratz T; Varga B; Müller W
    Rheumatol Int; 2002 Nov; 22(6):219-21. PubMed ID: 12426658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia.
    Späth M; Stratz T; Neeck G; Kötter I; Hammel B; Amberger CC; Haus U; Färber L; Pongratz D; Müller W
    Scand J Rheumatol; 2004; 33(4):267-70. PubMed ID: 15370724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory function of the 5-HT3 receptor antagonist tropisetron.
    Schneider EM; Ma X; Stratz T; Müller W; Lorenz I; Seeling WD
    Scand J Rheumatol Suppl; 2004; 119():34-40. PubMed ID: 15515411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analgesic effects of 5-HT3 receptor antagonists.
    Riering K; Rewerts C; Zieglgänsberger W
    Scand J Rheumatol Suppl; 2004; 119():19-23. PubMed ID: 15515407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 5-HT3 receptor antagonist tropisetron inhibits T cell activation by targeting the calcineurin pathway.
    Vega Lde L; Muñoz E; Calzado MA; Lieb K; Candelario-Jalil E; Gschaidmeir H; Färber L; Mueller W; Stratz T; Fiebich BL
    Biochem Pharmacol; 2005 Aug; 70(3):369-80. PubMed ID: 15922994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients.
    Färber L; Stratz TH; Brückle W; Späth M; Pongratz D; Lautenschläger J; Kötter I; Zöller B; Peter HH; Neeck G; Welzel D; Müller W;
    Int J Clin Pharmacol Res; 2001; 21(1):1-13. PubMed ID: 11708570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism.
    Pickering G; Loriot MA; Libert F; Eschalier A; Beaune P; Dubray C
    Clin Pharmacol Ther; 2006 Apr; 79(4):371-8. PubMed ID: 16580905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipruritic effects of two different 5-HT3 receptor antagonists and an antihistamine in haemodialysis patients.
    Weisshaar E; Dunker N; Röhl FW; Gollnick H
    Exp Dermatol; 2004 May; 13(5):298-304. PubMed ID: 15140020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibromyalgia treatment with intravenous tropisetron administration.
    Stratz T; Färber L; Varga B; Baumgartner C; Haus U; Müller W
    Drugs Exp Clin Res; 2001; 27(3):113-8. PubMed ID: 11447769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Local treatment of rheumatic diseases with the 5-HT3 receptor antagonist tropisetron].
    Stratz T; Müller W
    Schmerz; 2003 Jun; 17(3):200-3. PubMed ID: 12789487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 5-HT3 blockers in the treatment of the primary fibromyalgia syndrome: a 10-day open study with Tropisetron at a low dose.
    Samborski W; Stratz T; Lacki JK; Klama K; Mennet P; Müller W
    Mater Med Pol; 1996; 28(1):17-9. PubMed ID: 9088121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists--preliminary results.
    Späth M; Welzel D; Färber L
    Scand J Rheumatol Suppl; 2000; 113():72-7. PubMed ID: 11028837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous treatment of fibromyalgia with the 5-HT3 receptor antagonist tropisetron in a rheumatological practice.
    Tolk J; Kohnen R; Müller W
    Scand J Rheumatol Suppl; 2004; 119():72-5. PubMed ID: 15515420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-HT3 antagonist ICS 205-930 enhances naltrexone's effects on ethanol intake.
    Mhatre M; Pruthi R; Hensley K; Holloway F
    Eur J Pharmacol; 2004 May; 491(2-3):149-56. PubMed ID: 15140631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute treatment with 5-HT3 receptor antagonist, tropisetron, reduces immobility in intact female rats exposed to the forced swim test.
    Bravo G; Maswood S
    Pharmacol Biochem Behav; 2006 Oct; 85(2):362-8. PubMed ID: 17067664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer.
    Pinarli FG; Elli M; Dagdemir A; Baysal K; Acar S
    Pediatr Blood Cancer; 2006 Oct; 47(5):567-71. PubMed ID: 16317736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spectrum of use and tolerability of 5-HT3 receptor antagonists.
    Haus U; Späth M; Färber L
    Scand J Rheumatol Suppl; 2004; 119():12-8. PubMed ID: 15515406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.